The insulin like growth factor (IGF) axis plays a fundamental role in normal growth and
development, and when deregulated makes an important contribution to disease. Here, we …

Hematologic malignancies represent the fourth most frequently diagnosed cancer in
economically developed countries. In hematologic malignancies normal hematopoiesis is …

Patient-derived organoids (PDOs) are widely heralded as a drug-screening platform to
develop new anti-cancer therapies. Here, we use a drug-repurposing library to screen PDOs …

An increased tendency of genomic alterations during the life cycle of cells leads to genomic
instability, which is a major driving force for tumorigenesis. A considerable fraction of tumor …

Disulfiram (DSF) is an FDA approved anti-alcoholism drug in use for more than 60 years.
Recently, antitumor activity of the DSF/copper (DSF/Cu) complex has been identified. Its anti …

In addition to the fundamental role of insulin-like growth factor (IGF)/IGF-1 receptor (IGF-1R)
signaling dysregulation in cancer initiation and proliferation, the IGF/IGF-1R signaling also …

Abstract Background Children with Down syndrome (DS) have increased risk for developing
AML (DS-AMKL), and they usually experience severe therapy-related toxicities compared to …

We have previously shown that the insulin-like growth factor 1 receptor (IGF-1R)
translocates to the cell nucleus, where it binds to enhancer-like regions and increases gene …

Phase I clinical trial of AXL1717 for treatment of relapsed malignant astrocytomas: analysis of
dose and response - PMC Back to Top Skip to main content NIH NLM Logo Access keys NCBI …

Glioblastomas are highly resistant to radiation and chemotherapy. Currently, there are no
effective therapies for this type of tumor. Signaling mechanisms initiated by PDGFR and IGF …